- •PROGRESS IN BRAIN RESEARCH
- •List of Contributors
- •Preface
- •Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects
- •Introduction
- •Prevalence of glaucoma
- •PAC suspect
- •PACG
- •Incidence of glaucoma
- •Blinding effects of glaucoma
- •Abbreviations
- •Acknowledgment
- •References
- •Predictive models to estimate the risk of glaucoma development and progression
- •Risk assessment in ocular hypertension and glaucoma
- •Risk factors for glaucoma development
- •Intraocular pressure
- •Corneal thickness
- •Cup/disc ratio and pattern standard deviation
- •The need for predictive models
- •Predictive models for glaucoma development
- •Predictive models for glaucoma progression
- •Limitations of predictive models
- •References
- •Intraocular pressure and central corneal thickness
- •Main text
- •References
- •Angle-closure: risk factors, diagnosis and treatment
- •Introduction
- •Mechanism
- •Other causes of angle closure
- •Risk factors
- •Age and gender
- •Ethnicity
- •Ocular biometry
- •Genetics
- •Diagnosis
- •Acute primary angle closure
- •Angle assessment in angle closure
- •Gonioscopy technique
- •Ultrasound biomicroscopy (UBM)
- •Scanning peripheral anterior chamber depth analyzer (SPAC)
- •Management
- •Acute primary angle closure
- •Medical therapy
- •Argon laser peripheral iridoplasty (ALPI)
- •Laser peripheral iridotomy (PI)
- •Lens extraction
- •Monitoring for subsequent IOP rise in eyes with APAC
- •Fellow eye of APAC
- •Chronic primary angle-closure glaucoma (CACG)
- •Laser peripheral iridotomy
- •Laser iridoplasty
- •Medical therapy
- •Trabeculectomy
- •Lens extraction
- •Combined lens extraction and trabeculectomy surgery
- •Goniosynechialysis
- •Summary
- •List of abbreviations
- •References
- •Early diagnosis in glaucoma
- •Introduction
- •History and examination
- •Quantitative tests and the diagnostic process
- •Pretest probability
- •Test validity
- •Diagnostic test performance
- •Posttest probability
- •Combing test results
- •Selective tests of visual function
- •Early glaucoma diagnosis from quantitative test results
- •Progression to make a diagnosis
- •Conclusions
- •Abbreviations
- •References
- •Monitoring glaucoma progression
- •Introduction
- •Monitoring structural damage progression
- •Monitoring functional damage progression
- •Abbreviations
- •References
- •Standard automated perimetry and algorithms for monitoring glaucoma progression
- •Standard automated perimetry
- •Global indices
- •HFA: MD, SF, PSD, CPSD
- •Octopus indices: MD, SF, CLV
- •OCTOPUS seven-in-one report (Fig. 2)
- •SAP VF assessment: full-threshold strategy
- •SAP VF defects assessment: OHTS criteria
- •SAP VF defects assessment: AGIS criteria
- •SAP VF defects assessment: CIGTS
- •Fastpac
- •Swedish interactive threshold algorithm
- •SAP VF assessment: the glaucoma staging system
- •SAP: interocular asymmetries in OHTS
- •SAP, VF progression
- •SAP: the relationship to other functional and structural diagnostic tests in glaucoma
- •SAP, FDP-Matrix
- •SAP, SWAP, HPRP, FDT
- •SAP: the relationship between function and structure
- •SAP, confocal scanning laser ophthalmoscopy, SLP-VCC
- •SAP, optical coherence tomography
- •SAP and functional magnetic resonance imaging
- •References
- •Introduction
- •Retinal ganglion cells: anatomy and function
- •Is glaucoma damage selective for any subgroup of RGCs?
- •Segregation
- •Isolation
- •FDT: rationale and perimetric techniques
- •SWAP: rationale and perimetric techniques
- •FDT: clinical data
- •SWAP: clinical data
- •Clinical data comparing FDT and SWAP
- •Conclusions
- •References
- •Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma
- •The GDx scanning laser polarimeter
- •Serial analysis
- •Limits
- •The Heidelberg retinal tomograph
- •Limits
- •Conclusions
- •References
- •The role of OCT in glaucoma management
- •Introduction
- •How OCT works
- •How OCT is performed
- •Evaluation of RNFL thickness
- •Evaluation of optic disc
- •OCT in glaucoma management
- •New perspective
- •Abbreviations
- •References
- •Introduction
- •Technology
- •Visual stimulation
- •Reproducibility and habituation of RFonh
- •Retinal neural activity as assessed from the electroretinogram (ERG)
- •The Parvo (P)- and Magno (M)-cellular pathways
- •Physiology
- •Magnitude and time course of RFonh in humans
- •Varying the parameters of the stimulus on RFonh
- •Luminance versus chromatic modulation
- •Frequency
- •Effect of pattern stimulation
- •Neurovascular coupling in humans
- •Clinical application
- •RFonh in OHT and glaucoma patients
- •Discussion
- •FLDF and neurovascular coupling in humans
- •Comments on clinical application of FLDF in glaucoma
- •Conclusions and futures directions
- •Acknowledgements
- •References
- •Advances in neuroimaging of the visual pathways and their use in glaucoma
- •Introduction
- •Conventional MR imaging and the visual pathways
- •Diffusion MR imaging
- •Functional MR imaging
- •Proton MR spectroscopy
- •References
- •Primary open angle glaucoma: an overview on medical therapy
- •Introduction
- •When to treat
- •Whom to treat
- •Genetics
- •Race
- •Ocular and systemic abnormalities
- •Tonometry and pachymetry
- •How to treat
- •Beta-blockers
- •Prostaglandins
- •Alpha-agonists
- •Carbonic anhydrase inhibitors (CAIs)
- •Myotics
- •Fixed combinations
- •References
- •The treatment of normal-tension glaucoma
- •Introduction
- •Epidemiology
- •Clinical features
- •Optic disk
- •Central corneal thickness
- •Disease course
- •Risk factors
- •Intraocular pressure
- •Local vascular factors
- •Immune mechanisms
- •Differential diagnosis
- •Diagnostic evaluation
- •Therapy
- •IOP reduction
- •Systemic medications
- •Neuroprotection
- •Noncompliance
- •Genetics of NTG
- •Abbreviations
- •References
- •The management of exfoliative glaucoma
- •Introduction
- •Epidemiology
- •Ocular and systemic associations
- •Ocular associations
- •Systemic associations
- •Pathogenesis of exfoliation syndrome
- •Mechanisms of glaucoma development
- •Management
- •Medical therapy
- •Laser surgery
- •Operative surgery
- •Future treatment of exfoliation syndrome and exfoliative glaucoma
- •Treatment directed at exfoliation material
- •References
- •Laser therapies for glaucoma: new frontiers
- •Background
- •Laser iridotomy
- •Indications
- •Contraindications
- •Patient preparation
- •Technique
- •Nd:YAG laser iridectomy
- •Argon laser iridectomy
- •Complications
- •LASER trabeculoplasty
- •Treatment technique
- •Mechanism of action
- •Indications for treatment
- •Contraindications to treatment
- •Patient preparation and postoperative follow-up
- •Complications of the treatment
- •Selective laser trabeculoplasty
- •Results
- •LASER iridoplasty
- •Indications
- •Contraindications
- •Treatment technique
- •Complications
- •LASER cyclophotocoagulation
- •Introduction
- •Indications and contraindications
- •Patient preparation
- •Transpupillary cyclophotocoagulation
- •Endoscopic cyclophotocoagulation
- •Transscleral cyclophotocoagulation
- •Transscleral noncontact cyclophotocoagulation
- •Transscleral contact cyclophotocoagulation
- •Complications
- •Excimer laser trabeculotomy
- •References
- •Modulation of wound healing during and after glaucoma surgery
- •The process of wound healing
- •Using surgical and anatomical principles to modify therapy
- •Growth factors
- •Cellular proliferation and vascularization
- •Cell motility, matrix contraction and synthesis
- •Drug delivery
- •Future directions: total scarring control and tissue regeneration
- •Acknowledgments
- •References
- •Surgical alternative to trabeculectomy
- •Introduction
- •Deep sclerectomy
- •Viscocanalostomy
- •Conclusions
- •References
- •Modern aqueous shunt implantation: future challenges
- •Background
- •Current shunts and factors affecting their function
- •Shunt-related factors
- •Surface area
- •Plate material
- •Valved versus non-valved
- •Commercially available devices
- •Comparative studies
- •Patient and ocular factors
- •Severity of glaucoma damage
- •Tolerance of topical ocular hypotensive medications
- •Aqueous hyposecretion
- •Previous ocular surgery
- •Scleral thinning
- •Patient cooperation for and tolerance of potential slit-lamp interventions
- •Future challenges
- •Predictability
- •Cataract formation
- •The long-term effect on the cornea
- •References
- •Model systems for experimental studies: retinal ganglion cells in culture
- •Mixed RGCs in culture
- •Retinal explants
- •Glial cultures
- •RGC-5 cells
- •Differentiation of RGC-5 cells
- •RGC-5 cell neurites
- •Advantages and disadvantages of culture models
- •References
- •Rat models for glaucoma research
- •Rat models for glaucoma research
- •Use of animal models for POAG
- •Suitability of the rat for models of optic nerve damage in POAG
- •Methods for measuring IOP in rats
- •General considerations for measuring IOP in rats
- •Assessing optic nerve and retina damage
- •Experimental methods of producing elevated IOP
- •Laser treatment of limbal tissues
- •Episcleral vein cautery
- •Conclusions
- •Abbreviations
- •Acknowledgements
- •References
- •Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection
- •Introduction
- •The mouse as a model system
- •Mice are suitable models for studying IOP elevation in glaucoma
- •Tools for glaucoma research
- •Accurate IOP measurements are fundamental to the study of glaucoma
- •The future of IOP assessment
- •Assessment of RGC function
- •Mouse models of glaucoma
- •Primary open-angle glaucoma
- •MYOC
- •OPTN
- •Strategies for developing new models of POAG
- •Developmental glaucoma
- •Pigmentary glaucoma
- •Experimentally induced models of glaucoma
- •Mouse models to characterize processes involved in glaucomatous neurodegeneration
- •Similar patterns of glaucomatous damage occur in humans and mice
- •The lamina cribrosa is an important site of early glaucomatous damage
- •An insult occurs to the axons of RGCs within the lamina in glaucoma
- •What is the nature of the insult at the lamina?
- •Other changes occur in the retina in glaucoma
- •PERG and complement
- •Using mouse models to develop neuroprotective strategies
- •Somal protection
- •Axonal protection
- •Erythropoietin administration
- •Radiation-based treatment
- •References
- •Clinical trials in neuroprotection
- •Introduction
- •Methods of clinical studies
- •Issues in the design and conduct of clinical trials
- •Clinical trials of neuroprotection
- •Clinical trials of neuroprotection in ophthalmology
- •Endpoints
- •Neuroprotection and glaucoma
- •Conclusions
- •Abbreviations
- •References
- •Pathogenesis of ganglion ‘‘cell death’’ in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria
- •Introduction
- •Retinal ganglion cells and mitochondria
- •Possible causes for ganglion cell death in glaucoma
- •Mitochondrial functions and apoptosis
- •Mitochondrial function enhancement and the attenuation of ganglion cell death
- •Creatine
- •Nicotinamide
- •Epigallocatechin gallate
- •Conclusion
- •References
- •Astrocytes in glaucomatous optic neuropathy
- •Introduction
- •Quiescent astrocytes
- •Reactive astrocytes in glaucoma
- •Signal transduction in glaucomatous astrocytes
- •Protein tyrosine kinases (PTKs)
- •Serine/threonine protein mitogen-activated kinases (MAPKs)
- •G protein-coupled receptors
- •Ras superfamily of small G proteins
- •Astrocyte migration in the glaucomatous optic nerve head
- •Cell adhesion of ONH astrocytes
- •Connective tissue changes in the glaucomatous optic nerve head
- •Extracellular matrix synthesis by ONH astrocytes
- •Extracellular matrix degradation by reactive astrocytes
- •Oxidative stress in ONH astrocytes
- •Conclusions
- •Acknowledgments
- •References
- •Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation
- •Glaucoma as a neurodegenerative disease
- •Oxidative stress and free radicals
- •Excessive glutamate, increased calcium levels, and excitotoxicity
- •Deprivation of neurotrophins and growth factors
- •Abnormal accumulation of proteins
- •Pharmacological neuroprotection for glaucoma
- •Protection of the retinal ganglion cells involves the immune system
- •Searching for an antigen for potential glaucoma therapy
- •Concluding remarks
- •References
- •Oxidative stress and glaucoma: injury in the anterior segment of the eye
- •Introduction
- •Oxidative stress
- •Trabecular meshwork
- •IOP increase and free radicals
- •Glaucomatous cascade
- •Nitric oxide and endothelins
- •Extracellular matrix
- •Metalloproteinases
- •Other factors of interest
- •Therapeutic and preventive substances of interest in glaucoma
- •Ginkgo biloba extract
- •Green tea
- •Ginseng
- •Memantine and its derivates
- •Conclusions
- •Abbreviations
- •References
- •Conclusions on neuroprotective treatment targets in glaucoma
- •Acknowledgments
- •References
- •Involvement of the Bcl2 gene family in the signaling and control of retinal ganglion cell death
- •Introduction
- •Intrinsic apoptosis vs. extrinsic apoptosis
- •The Bcl2 family of proteins
- •The requirement of BAX for RGC soma death
- •BH3-only proteins and the early signaling of ganglion cell apoptosis
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •Assessment of neuroprotection in the retina with DARC
- •Introduction
- •DARC
- •Introducing the DARC technique
- •Annexin 5-labeled apoptosis and ophthalmoloscopy
- •Detection of RGC apoptosis in glaucoma-related animal models with DARC
- •Assessment of glutamate modulation with DARC
- •Glutamate at synaptic endings
- •Glutamate excitotoxicity in glaucoma
- •Assessment of coenzyme Q10 in glaucoma-related models with DARC
- •Summary
- •Abbreviations
- •Acknowledgment
- •References
- •Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection
- •Introduction
- •The endocannabinoid system in the eye
- •The IOP-lowering effects of endocannabinoids
- •Endocannabinoids and neuroprotection
- •Conclusions
- •References
- •Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration
- •Retinal ganglion cells, retino-geniculate neurons
- •Lateral geniculate nucleus
- •Mechanisms of RGC injury in glaucoma
- •Transsynaptic degeneration of the lateral geniculate nucleus in glaucoma
- •Neural degeneration in magno-, parvo-, and koniocellular LGN layers
- •Visual cortex in glaucoma
- •Neuropathology of glaucoma in the visual pathways in the human brain
- •Mechanisms of glaucoma damage in the central visual pathways
- •Implications of central visual system injury in glaucoma
- •Conclusion
- •Acknowledgments
- •References
- •Clinical relevance of optic neuropathy
- •Is there a remodeling of retinal circuitry?
- •Behavioral consequences of glaucoma
- •Glaucoma as a neurodegenerative disease versus neuroplasticity and adaptive changes
- •Future directions
- •Acknowledgment
- •References
- •Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma
- •Introduction
- •Channel properties of NMDA receptors correlated with excitotoxicity
- •Downstream signaling cascades after overactivation of NMDA receptors
- •Relevance of excitotoxicity to glaucoma
- •Therapeutic approaches to prevent RGC death by targeting the pathways involved in NMDA excitotoxicity
- •Drugs targeting NMDA receptors
- •Kinetics of NMDA receptor antagonists
- •Memantine
- •NitroMemantines
- •Drugs targeting downstream signaling molecules in NMDA-induced cell death pathways
- •p38 MAPK inhibitors
- •Averting caspase-mediated neurodegeneration
- •Abbreviations
- •Acknowledgments
- •References
- •Stem cells for neuroprotection in glaucoma
- •Introduction
- •Glaucoma as a model of neurodegenerative disease
- •Why use stem cells for neuroprotective therapy?
- •Stem cell sources
- •Neuroprotection by transplanted stem cells
- •Endogenous stem cells
- •Key challenges
- •Conclusion
- •Abbreviations
- •Acknowledgments
- •References
- •The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells
- •Introduction
- •Glaucoma and the RGCs
- •Are other retinal cells affected in glaucoma?
- •Retinal ischemia related glaucoma
- •Excitotoxicity and the retina
- •Signal transduction
- •NMDA receptor antagonists and CaMKII
- •Caspase-3 activation in NMDA-induced retinal cell death and its inhibition by m-AIP
- •BDNF and neuroprotection of RGCs
- •Summary and conclusions
- •Abbreviations
- •Acknowledgments
- •References
- •Evidence of the neuroprotective role of citicoline in glaucoma patients
- •Introduction
- •Patients: selection and recruitment criteria
- •Pharmacological treatment protocol
- •Methodology of visual function evaluation: electrophysiological examinations
- •PERG recordings
- •VEP recordings
- •Statistic evaluation of electrophysiological results
- •Electrophysiological (PERG and VEP) responses in OAG patients after the second period of evaluation
- •Effects of citicoline on retinal function in glaucoma patients: neurophysiological implications
- •Effects of citicoline on neural conduction along the visual pathways in glaucoma patients: neurophysiological implications
- •Possibility of neuroprotective role of citicoline in glaucoma patients
- •Conclusive remarks
- •Abbreviations
- •References
- •Neuroprotection: VEGF, IL-6, and clusterin: the dark side of the moon
- •Neuroprotection: VEGF-A, a shared growth factor
- •VEGF-A isoforms
- •VEGF-A receptors
- •Angiogenesis, mitogenesis, and endothelial survival
- •Neurotrophic and neuroprotective effect
- •Intravitreal VEGF inhibition therapy and neuroretina toxicity
- •Neuroprotection: clusterin, a multifunctional protein
- •Clusterin/ApoJ: a debated physiological role
- •Clusterin and diseases
- •Clusterin and the nervous system
- •Neuroprotection: IL-6, VEGF, clusterin, and glaucoma
- •Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection
- •Introduction
- •Ischemia model
- •Neuroprotective effect of Coenzyme Q10 against cell loss yielded by transient ischemia in the RGC layer
- •Retinal ischemia and glutamate
- •Coenzyme Q10 minimizes glutamate increase induced by ischemia/reperfusion
- •Summary
- •Acknowledgment
- •References
- •17beta-Estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat
- •Methods
- •Morphometric analysis
- •Microdialysis
- •Drug application
- •Statistical analysis
- •Results
- •17beta-Estradiol pretreatment minimizes RGC loss
- •Discussion
- •Acknowledgment
C. Nucci et al. (Eds.)
Progress in Brain Research, Vol. 173
ISSN 0079-6123
Copyright r 2008 Elsevier B.V. All rights reserved
CHAPTER 27
Oxidative stress and glaucoma: injury in the anterior segment of the eye
1 |
and A. Izzotti |
2, |
S.C. Sacca` |
|
1Division of Ophthalmology, St. Martino Hospital, Genoa, Italy
2Department of Health Sciences, Faculty of Medicine, University of Genoa, Genoa, Italy
Abstract: The perturbation of the pro-oxidant/antioxidant balance can lead to increased oxidative damage, especially when the first line of antioxidant defense weakens with age. Chronic changes in the composition of factors present in aqueous or vitreous humor may induce alterations both in trabecular cells and in cells of the optic nerve head. Free radicals and reactive oxygen species are able to affect the cellularity of the human trabecular meshwork (HTM). These findings suggest that intraocular pressure increase, which characterizes most glaucomas, is related to oxidative and degenerative processes affecting the HTM and, more specifically, its endothelial cells. This supports the theory that glaucomatous damage is the pathophysiological consequence of oxidative stress. Glaucomatous subjects might have a genetic predisposition, rendering them more susceptible to reactive oxygen species-induced damage. It is likely that specific genetic factors contribute to both the elevation of IOP and susceptibility of the optic nerve/ retinal ganglion cells (RGCs) to degeneration. Thus, oxidative stress plays a fundamental role during the arising of glaucoma-associated lesions, first in the HTM and then, when the balance between nitric oxide and endothelins is broken, in neuronal cell. Vascular damage and hypoxia, often associated with glaucoma, lead to apoptosis of RGCs and may also contribute to the induction of oxidative damage to the HTM. On the whole, these findings support the hypothesis that oxidative damage is an important step in the pathogenesis of primary open-angle glaucoma and might be a relevant target for both prevention and therapy.
Keywords: oxidative stress; DNA damage; primary open-angle glaucoma; trabecular meshwork
Introduction
The destructive action of free radicals is focused largely on cells, particularly on membrane lipids (due to the peroxidation process), sugars, phosphates and proteins, and DNA, which is one of the major factor contributing to cell aging. These
Corresponding author. Tel.: 010-353-8394; Fax: 010-353-8504; E-mail: izzotti@unige.it
cellular alterations in aged individuals and senescent cells are similar and they are related to cellular response to sublethal doses of oxidative stress. These alterations lead to a decline in mitochondrial respiratory functions and to a decrease in the capacities of degradation of proteins and other macromolecules, establishing an early cellular dysfunction (Lee and Wei, 2001).
Light, continually penetrating the eye through its tissues, produces a large number of free radicals that are often at the basis of the main diseases of
DOI: 10.1016/S0079-6123(08)01127-8 |
385 |
386
the eye, such as age-related macular degeneration, cataract, and glaucoma.
Many findings lead us to believe that these diseases are the cytopathological consequence of an unfavorable state between the intracellular concentration of free radicals and the cells’ capacity to neutralize them through an increase in endogenous production of free radicals, a reduction of antioxidant molecules and/or a decrease of the capacity to repair the oxidative damage on cellular macromolecules.
The main eye diseases have a common pathogenetic mechanism: a long period of latency between induction and clinical manifestation with a multifactorial etiology resulting from the interaction between environmental risk factors and heightened individual genetic susceptibility.
In particular, in glaucoma, free radicals have different target tissues and, especially, in the anterior segment of the eye, they affect the trabecular meshwork (TM) and, more specifically, its endothelium. Contemporarily, in the posterior segment, free radicals affect/involve retinal ganglion cells (RGCs) and optic nerve head (ONH) in its extracellular component, leading to a series of events defined as ‘‘the glaucomatous cascade.’’
Oxidative stress
The loss of electrons from the outer orbit of atoms is defined as ‘‘oxidation’’ and leads to the formation of highly reactive molecules. A molecular species whose atoms contain one or more unpaired electrons in their outer orbits is defined as a free radical. This structure gives rise to the fundamental property of such molecules: instability. Indeed, in order to restore the equilibrium of their magnetic fields, atoms containing unpaired electrons tend to capture electrons from other atoms of nearby molecules, which in turn become free radicals, thus a chain reaction is triggered.
Organisms use oxygen to oxidize food; nutrients composed of carbohydrates, proteins, and fats are oxidized to carbon dioxide and water. The energy released during the oxidation process is stored in the form of adenosine triphosphate (ATP) and is subsequently used in numerous metabolic reactions.
While oxygen is essential to animal metabolism, it can also be harmful. Indeed, numerous uncontrolled oxidation reactions (auto-oxidation) may take place in the presence of oxygen and can cause cell damage. Free radicals are oxygen compounds resulting from the numerous metabolic reactions involving oxygen. They tend to readdress their imbalance by ‘‘attacking’’ nearby molecules in order to recover their missing electron, thereby making other molecules unstable. The ensuing chain reaction gives rise to the formation of new compounds, some of which may be toxic.
Although many atoms and molecules can form free radicals in vivo, the most important for biological systems seem to be the radical ions associated with oxygen reduction. The diatomic molecules of oxygen (O2) can be reduced to form the superoxide (O2 ) and hydroxyl (OH ) radicals. These oxygen free radicals have an enormous potential to harm living organisms. The superoxide is not particularly reactive in aqueous environments, while it is highly destructive in the lipophilic linings of biological membranes. The hydroxyl form is the most reactive and the most dangerous of all free radicals: it survives only momentarily before combining with one of the molecules nearby, such as DNA, proteins, and other macromolecules.
In physiological conditions, there is a balance between the endogenous production of free radicals and their neutralization by antioxidant defense mechanisms. When the production of radicals exceeds the organism’s capacity to neutralize them (‘‘scavenger’’ activity) or when antioxidant substances activity decreases, damage ensues.
Free radicals are neutralized both by a range of enzymes, such as superoxide dismutase (SOD), glutathione peroxidase, or catalase, and by numerous molecules that are either endogenously produced, such as glutathione (GSH), or dietary introduced, such as flavonoids, vitamins C, E, and others. These molecules are able to capture free radicals and accept the unpaired electron and ‘‘pass it on.’’ Molecules with the most effective action are those which have aromatic rings, particularly those with several hydroxyl groups, such as the polyphenols.
The most well-known free radical chain reaction is lipid peroxidation. In this process, a free radical removes a hydrogen atom from a lateral chain of a polyunsaturated fatty acid. Consequently, the carbon atom from which the hydrogen atom has been removed is left with an unpaired electron. In other words, the lateral chain of the fatty acid is transformed into a reactive free radical. These carbon atom radicals (lipids) normally end up combining with molecular oxygen (O2) in the membrane to produce a peroxyl radical lipid (O2). O2 is extremely reactive and triggers a chain reaction within the lateral chains of the polyunsaturated fatty acids. Over time, peroxidation produces enough peroxidated lipids to damage the structure and fluidity of the membrane. Through a similar mechanism, peroxidation can cause severe damage to the essential proteins of the membrane.
The lateral chains of the polyunsaturated fatty acids, which guarantee the necessary fluidity of the membrane lipids, are particularly sensitive to attack by free radicals. If the free radicals of the chains are not deactivated, their chemical reactivity can damage all types of cellular macromolecules. The main targets of peroxidation reactions are proteins, cell membranes, and nucleic acids (DNA and RNA), including mitochondrial DNA (mtDNA). Indeed, mtDNA is less protected than nuclear DNA, and is therefore more sensitive to free radical attack (De Grey, 1997). mtDNA damage is another possible mechanism involved in the etiopathogenesis of degenerative diseases.
Peroxidation phenomena in the organism are countered by antioxidant compounds, which inhibit the formation of free radicals. These compounds include water-soluble antioxidants (e.g., ascorbic acid, cysteine, GSH), lipid-insoluble antioxidants (e.g., tocopherols and retinols), and enzymes such as SOD, which catalyzes the transformation of free radicals into hydrogen peroxide. Although hydrogen peroxide is also an active oxygen compound, it can be further transformed into oxygen and water by catalase. Also, several metal-binding proteins (e.g., transferrin) (Babizhayev and Costa, 1994; Rose et al., 1998) and flavonoids (e.g., genistein, diazine, glycyrrhizin, etc.) (Kapiotis et al., 1997; Wang et al., 1998; Tang et al., 2007) have an antioxidant activity.
387
Table 1. Many studies underscore the role of endogenous oxidative damage in the pathogenesis of glaucoma
ROS effects in the eye
Induction |
Inhibition |
|
|
Protein synthesis |
HTM cellularity |
H2O2 |
HTM mobility |
Catalase |
|
Vascular permeability factor |
Glutamate synthase |
Vascular endothelial growth |
Na+-dependent glutamate |
factor |
transporter |
Ischemia |
Glutamate reuptake by |
|
astroglial cells |
Heat shock proteins |
Ionic imbalance |
Matrix components |
Glutathione |
Peroxynitrite |
Expression of neural cell |
|
adhesion molecule |
Endothelins |
Na+, K+-ATPase |
ECM remodeling |
Ascorbate |
TGF |
Antioxidant activity |
|
|
Note: This interpretation is in agreement with both vascular and mechanical pathogenic theories. The set of processes that make up the glaucomatous cascade triggered by free radicals results in the progressive apoptotic degeneration of trabecular meshwork, retina, and optic nerve.
The formation of metal-mediated free radicals causes various modifications of DNA nucleotides, enhanced lipid peroxidation, and altered calcium and sulfhydryl homeostasis. Lipid peroxides, formed by the attack of free radicals on polyunsaturated fatty acid residues of phospholipids, can further react with redox metals, finally producing mutagenic and other exocyclic DNA adducts (Valko et al., 2005), such as 8-hydroxy-2u- deoxyguanosine (8-OH-dG), which is an indicator of oxidative DNA damage.
Concerning eye diseases, all this phenomena are particularly important, above all in the pathogenesis of glaucoma (Table 1), where age and oxidative stress appear to play a fundamental pathogenic role (Sacca`et al., 2007).
Trabecular meshwork
Glaucoma is a group of optic neuropathies characterized by a progressive degeneration of RGCs and visual-field damage, which represents the final common pathway resulting from a number of different conditions that can affect the
388
eye. Even if this disease has been known from the time of Hippocrates (Nathan, 2000), its pathogenesis is still misunderstood.
The chambers of the eye are filled with aqueous humor (AH), a fluid with an ionic composition very similar to blood plasma, with two main functions: to provide nutrients to eye tissues (e.g., cornea, iris, and lens) and to maintain intraocular pressure (IOP). Therefore, the anterior chamber of the eye can be regarded as a highly specialized vascular compartment whose inner walls are composed of the endothelia of iris, cornea, and TM (Brandt and O’Donnell, 1999).
In most cases, glaucoma is accompanied by an increase of the IOP. Ocular hypertension is one of the major risk factors for the development and progression of primary open-angle glaucoma (POAG), a leading cause of blindness. TM is a tissue located in the anterior chamber angle of the eye, and it is a crucial determinant of IOP even if, at the moment, many aspects of the regulation of AH outflow remain unclear. Nevertheless, it is known that the region of maximal resistance to AH outflow resides at the peripheral juxtacanalicular TM, which connects the TM to the Schlemm’s canal (Johnson and Johnson, 2001). TM is directly involved in the regulation of AH outflow (Wiederholt et al., 1995). The subendothelial region of Schlemm’s canal does not form a continuous fluid system, and the pathways through the connective tissue of the cribriform region are responsible for outflow facility and determine the filtration area of the inner wall of Schlemm’s canal (Lutjen-Drecoll, 1973). This tissue has unique morphologic and functional properties involved in the regulation of AH outflow. The conventional outflow pathway is organized with a plumbing arrangement for maintaining a fluid barrier to prevent the passage of AH, consisting of trabecular lamellae covered with HTM cells, in front of a resistor, consisting of juxtacanalicular HTM cells and the inner wall of Schlemm’s canal. The outermost juxtacanalicular or cribriform region has no collagenous beams, but rather several cell layers which some authors claim to be immersed in loose extracellular material/matrix (Tian et al., 2000). TM cells also regulate the formation and turnover of
extracellular matrix (ECM) (Yue, 1996). A disproportionate accretion of ECM occurs in the TM region of POAG eyes, and this buildup is responsible for the development of greater resistance to AH outflow, resulting in increased IOP (Rohen and Witmer, 1972; Lee and Grierson, 1974). The main resistance to the AH outflow is located in the TM directly underneath the inner wall of Schlemm’s canal (Maepea and Bill, 1992). The inner wall of Schlemm’s canal is unique, sharing extraordinary characteristics with both types of specialized endothelia: lymphatic and blood capillary endothelia (Ramos et al., 2007). In this layer, there are the ‘‘giant vacuoles.’’ They are really outpouchings of the endothelium into Schlemm’s canal, caused by the pressure drop across inner wall endothelial cells (Brilakis and Johnson, 2001). The distal openings, or pores, in these vacuoles are a second feature of the inner wall endothelium (Johnson, 2006). The majority of these pores are transcellular. The transcellular pores do not connect the extracellular fluid with the cellular cytoplasm. These pores usually form on giant vacuoles because it is in this region in which the cell is greatly attenuated and the cytoplasm becomes thin (Johnson, 2006). When cell thickness is reduced below a critical value, vascular endothelium can form transcellular pores involved in transport processes (Neal and Michel, 1996; Savla et al., 2002). The region immediately underlying the inner wall and basement membrane is the juxtacanalicular connective tissue having many large spaces filled with an ECM gel (Ethier et al., 1986; Ten Hulzen and Johnson, 1996). Furthermore, the ECM may generate significant aqueous outflow resistance (Bradley et al., 1998). Studies found that some inner wall pores may be artifacts of the fixation process (Sit et al., 1997; Ethier et al., 1998). Actually, TM pores contribute only 10% of the aqueous outflow resistance (Sit et al., 1997). As stated by Johnson, ‘‘a fundamental reassessment of the mechanism by which AH crosses the inner wall endothelium is necessary’’ (Johnson et al., 2002). The concept of the outflow system as a passive filter has been surpassed; the structures through which AH leaves the anterior chamber may be objects of physical or pharmacologic manipulation for therapeutic
